SOURCE: Genmed Holding Corp.

Genmed Holding Corp.

May 23, 2011 09:00 ET

Genmed Raises $2.75 Million Through Bond Offering

AMSTERDAM, NETHERLANDS--(Marketwire - May 23, 2011) - Genmed Holding Corp. (OTCBB: GENM) has announced that it has now raised more than $2.75 million U.S. Dollars through its bond offering. The funds will be used for further generic drug registrations within the European Union. The company is currently licensed to distribute and market the drug Paracetamol, otherwise known as Acetaminophen, in more than seven countries including the Netherlands, Belgium, Luxemburg, Ireland, United Kingdom, Germany, and France.

The Company believes it now has enough funding to register another 6 generic drugs over the next 24-36 months. Genmed plans to register 16 generic drugs in total over the next five to seven years which represent a market of more than EUR 9.4 billion Euros, or more than $13 billion U.S. Dollars. The Company estimates the next six registrations represent a total market value of approximately EUR 3.5 billion Euros, or approximately $5 billion U.S. Dollars.

Genmed Chief Executive Officer Erwin Bouwens commented on the fund raising achievement by saying, "This milestone is testament to our investors' belief in our Company and to the value we are creating by registering these generic pharmaceuticals. The registration process is both capital and human resource intensive. However, since we have already successfully been through the process with Paracetemol, we are anticipating a slightly easier road with the next several registrations."

About Genmed Holding Corp.

Genmed Holding Corp. is a fully reporting publicly traded company that trades on the OTC under the symbol GENM. It is a United States and Dutch based company focusing on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. The Company began its generic drug business in 2008 and today operates primarily through its 100% owned subsidiary Genmed B.V., which is registered in the Netherlands. The Company is led by an experienced management team and board who have considerable and highly relevant experience in product development, registration, sales, marketing, distribution, operations, and financial administration.

For Additional Information, Go to the Website: www.genmed.nl

This press release contains certain "forward-looking statements" within the meaning of federal securities laws including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions. Although the Company believes that the statements were reasonable when made, these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of our products and services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management or increased government regulation.